These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 26208907)

  • 1. STAT3 Inhibition Enhances the Therapeutic Efficacy of Immunogenic Chemotherapy by Stimulating Type 1 Interferon Production by Cancer Cells.
    Yang H; Yamazaki T; Pietrocola F; Zhou H; Zitvogel L; Ma Y; Kroemer G
    Cancer Res; 2015 Sep; 75(18):3812-22. PubMed ID: 26208907
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Th17 cells inhibit CD8
    Wang D; Yu W; Lian J; Wu Q; Liu S; Yang L; Li F; Huang L; Chen X; Zhang Z; Li A; Liu J; Sun Z; Wang J; Yuan W; Zhang Y
    J Hematol Oncol; 2020 Jun; 13(1):68. PubMed ID: 32503584
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abundant expression of CXCL9 (MIG) by stromal cells that include dendritic cells and accumulation of CXCR3+ T cells in lymphocyte-rich gastric carcinoma.
    Ohtani H; Jin Z; Takegawa S; Nakayama T; Yoshie O
    J Pathol; 2009 Jan; 217(1):21-31. PubMed ID: 18980207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.
    Guha P; Gardell J; Darpolor J; Cunetta M; Lima M; Miller G; Espat NJ; Junghans RP; Katz SC
    Oncogene; 2019 Jan; 38(4):533-548. PubMed ID: 30158673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induction of the genes for Cxcl9 and Cxcl10 is dependent on IFN-gamma but shows differential cellular expression in experimental autoimmune encephalomyelitis and by astrocytes and microglia in vitro.
    Carter SL; Müller M; Manders PM; Campbell IL
    Glia; 2007 Dec; 55(16):1728-39. PubMed ID: 17902170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pivotal role of innate and adaptive immunity in anthracycline chemotherapy of established tumors.
    Mattarollo SR; Loi S; Duret H; Ma Y; Zitvogel L; Smyth MJ
    Cancer Res; 2011 Jul; 71(14):4809-20. PubMed ID: 21646474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. IL-17 inhibits CXCL9/10-mediated recruitment of CD8
    Chen J; Ye X; Pitmon E; Lu M; Wan J; Jellison ER; Adler AJ; Vella AT; Wang K
    J Immunother Cancer; 2019 Nov; 7(1):324. PubMed ID: 31775909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. STAT3 in CD8+ T Cells Inhibits Their Tumor Accumulation by Downregulating CXCR3/CXCL10 Axis.
    Yue C; Shen S; Deng J; Priceman SJ; Li W; Huang A; Yu H
    Cancer Immunol Res; 2015 Aug; 3(8):864-870. PubMed ID: 26025380
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes.
    Lu C; Klement JD; Ibrahim ML; Xiao W; Redd PS; Nayak-Kapoor A; Zhou G; Liu K
    J Immunother Cancer; 2019 Jun; 7(1):157. PubMed ID: 31228946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced cancer immunotherapy using STAT3-depleted dendritic cells with high Th1-inducing ability and resistance to cancer cell-derived inhibitory factors.
    Iwata-Kajihara T; Sumimoto H; Kawamura N; Ueda R; Takahashi T; Mizuguchi H; Miyagishi M; Takeda K; Kawakami Y
    J Immunol; 2011 Jul; 187(1):27-36. PubMed ID: 21632716
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy.
    Sistigu A; Yamazaki T; Vacchelli E; Chaba K; Enot DP; Adam J; Vitale I; Goubar A; Baracco EE; Remédios C; Fend L; Hannani D; Aymeric L; Ma Y; Niso-Santano M; Kepp O; Schultze JL; Tüting T; Belardelli F; Bracci L; La Sorsa V; Ziccheddu G; Sestili P; Urbani F; Delorenzi M; Lacroix-Triki M; Quidville V; Conforti R; Spano JP; Pusztai L; Poirier-Colame V; Delaloge S; Penault-Llorca F; Ladoire S; Arnould L; Cyrta J; Dessoliers MC; Eggermont A; Bianchi ME; Pittet M; Engblom C; Pfirschke C; Préville X; Uzè G; Schreiber RD; Chow MT; Smyth MJ; Proietti E; André F; Kroemer G; Zitvogel L
    Nat Med; 2014 Nov; 20(11):1301-9. PubMed ID: 25344738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GPR182 limits antitumor immunity via chemokine scavenging in mouse melanoma models.
    Torphy RJ; Sun Y; Lin R; Caffrey-Carr A; Fujiwara Y; Ho F; Miller EN; McCarter MD; Lyons TR; Schulick RD; Kedl RM; Zhu Y
    Nat Commun; 2022 Jan; 13(1):97. PubMed ID: 35013216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of STAT3 promotes the efficacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma.
    Fujita M; Zhu X; Sasaki K; Ueda R; Low KL; Pollack IF; Okada H
    J Immunol; 2008 Feb; 180(4):2089-98. PubMed ID: 18250414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fungal pattern receptors down-regulate the inflammatory response by a cross-inhibitory mechanism independent of interleukin-10 production.
    Rodríguez M; Márquez S; de la Rosa JV; Alonso S; Castrillo A; Sánchez Crespo M; Fernández N
    Immunology; 2017 Feb; 150(2):184-198. PubMed ID: 27709605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression of autoimmune hepatitis is mediated by IL-18-producing dendritic cells and hepatic CXCL9 expression in mice.
    Ikeda A; Aoki N; Kido M; Iwamoto S; Nishiura H; Maruoka R; Chiba T; Watanabe N
    Hepatology; 2014 Jul; 60(1):224-36. PubMed ID: 24700550
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
    Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
    Oncogene; 1999 Apr; 18(13):2241-51. PubMed ID: 10327070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three steps to breaking immune tolerance to lymphoma: a microparticle approach.
    Makkouk A; Joshi VB; Lemke CD; Wongrakpanich A; Olivier AK; Blackwell SE; Salem AK; Weiner GJ
    Cancer Immunol Res; 2015 Apr; 3(4):389-98. PubMed ID: 25627654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors.
    Dangaj D; Bruand M; Grimm AJ; Ronet C; Barras D; Duttagupta PA; Lanitis E; Duraiswamy J; Tanyi JL; Benencia F; Conejo-Garcia J; Ramay HR; Montone KT; Powell DJ; Gimotty PA; Facciabene A; Jackson DG; Weber JS; Rodig SJ; Hodi SF; Kandalaft LE; Irving M; Zhang L; Foukas P; Rusakiewicz S; Delorenzi M; Coukos G
    Cancer Cell; 2019 Jun; 35(6):885-900.e10. PubMed ID: 31185212
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CXCL9 chemokine promotes the progression of human pancreatic adenocarcinoma through STAT3-dependent cytotoxic T lymphocyte suppression.
    Gao HF; Cheng CS; Tang J; Li Y; Chen H; Meng ZQ; Chen Z; Chen LY
    Aging (Albany NY); 2020 Jan; 12(1):502-517. PubMed ID: 31913856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CXCL10 promotes invasion-related properties in human colorectal carcinoma cells.
    Zipin-Roitman A; Meshel T; Sagi-Assif O; Shalmon B; Avivi C; Pfeffer RM; Witz IP; Ben-Baruch A
    Cancer Res; 2007 Apr; 67(7):3396-405. PubMed ID: 17409450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.